Multinational pharmaceutical companies have published 2019 financial statements, what are the highlights of their performance?

[pharmaceutical network industry trends] recently, Geely announced its 2019 performance, showing a total annual revenue of 22.449 billion US dollars, an increase of 1.5% compared with 2018 Among them, the sales revenue of AIDS products reached US $16.438 billion, an increase of 12% compared with 2018, and the proportion in the company's total revenue increased to 73.32%, which is the core business segment of Geely In addition, with the approval in China, gemrid hepatitis B drug vemlidy has opened up a huge market and achieved 52% growth Geely expects to generate $1 billion in revenue in 2022 as it penetrates the U.S market and drives the Chinese market In fact, in addition to Geely, Johnson & Johnson, Pfizer, Novartis and other multinational pharmaceutical companies have also recently released 2019 performance reports For example, on January 22, J & J announced its 2019 results, achieving a total revenue of US $82.059 billion, an increase of 0.6% year on year Among them, the revenue of pharmaceutical business segment is US $42.198 billion (+ 3.6%), the revenue of medical device business segment is US $25.963 billion (- 3.8%), and the revenue of consumer health business segment is US $13.898 billion (+ 0.3%) The pharmaceutical business segment is still the main driving force for Johnson & Johnson to maintain growth, while the two disease areas with rapid growth are autoimmune diseases (US $13.95 billion, + 6.3%), and tumors (US $10.692 billion, + 8.6%) On January 28, Pfizer announced its 2019 results, achieving a total revenue of US $52.75 billion, down 1% year on year From the perspective of segment business, the total revenue of biopharmaceutical business for the whole year was US $39.4 billion, an increase of 8%; the revenue of general strength business reached US $10.233 billion, a decrease of 16% However, China's market revenue increased by 7%, which was mainly driven by a series of brand drugs Viagra, Celebrex, Zoloft and Lyrica, which have passed the patent period These drugs have not yet been purchased in volume, and at the same time, they are fighting against the impact of sales decline of Lipitor (Lipitor) and Norvasc (lotoxir), which have entered into volume procurement Among them, the financial report also showed that the growth of Pfizer's biopharmaceutical business in the fourth quarter was driven by the good performance of anti infection products and Peier 13 in the Chinese market On January 29, Novartis announced its 2019 results According to the financial report, Novartis achieved revenue of US $47.445 billion in 2019, up 6% year on year Among them, the revenue of innovative medicine business reached US $37.714 billion, an increase of 8% year-on-year; the revenue of Sandoz, the generic medicine business unit, was US $9.731 billion, a decrease of 1% year-on-year It is worth noting that Novartis first mentioned China's performance in its financial statements According to the financial report, the sales volume of Novartis China market has reached double-digit growth and is expected to double in 2024 In addition, Wan Sihan, CEO of Novartis group, said at JPMO conference a while ago that he expected to launch 50 NDA plans (new drug applications) in China in the next five years, with an average of 10 per year At present, from the perspective of the overall performance growth of multinational pharmaceutical enterprises, the highlight of the performance growth of all parties is not very obvious in terms of numbers, and the effect of stimulating the performance recovery through M & A, divestiture and other measures remains to be seen But it is clear that for multinational pharmaceutical companies, the Chinese market may still be a huge potential growth space in emerging markets For Gilead, since 2017, Gilead has successively obtained the approval of China's nmpa for eight drugs, and four new drugs have entered the national medical insurance catalog, namely, hepatitis B drug vemlidy, hepatitis C drug epclusa, hepatitis C drug harvoni, and HIV drug genvoya In addition, under the new crown epidemic at the beginning of the year, Geely Germany and China have been frequently concerned by all parties, and its klitschke and radcivir have been included in the study If the efficacy of its drugs is verified, it is clear that the Chinese market will bring huge orders for them In fact, due to China's large population base and huge market, some drugs that have passed the patent period can still maintain a good growth momentum in China For example, Lipitor, Plavix, Keding and other drugs from 2013 to 2017, the contribution rate of China's market accounts for more than half of the world Therefore, the Chinese market is an indispensable performance development market for multinational pharmaceutical enterprises At present, in order to adapt to the new market direction, multinational pharmaceutical companies are actively seeking change, at the same time, the competition and cooperation relationship with local pharmaceutical companies is also constantly in-depth.